Osteoarthritis (OA) is the most common degenerative disorder and can be characterized by a progressive degradation and loss of articular cartilage, hypertrophic bone changes with osteophyte formation, subchondral bone remodelling, and chronic inflammation of the synovial membrane. This disease most commonly affects the joints of the knees, hands, feet, and spine and is relatively common in shoulder and hip articular joints as well. The increased expression of inflammatory and catabolic mediators, combined with subchondral bone remodelling results in pain, stiffness and reduced joint motion. The goal of this project was to formulate, characterize and evaluate microparticles loaded with curcumin that can sustain a drug release over a period of months during in vitro release.